Evolent (EVH) Q2 2026 earnings review
Massive Top-Line Growth Masked by a Sharp Profitability Drop
Evolent posted a massive 47% YoY revenue surge to $653M, fueled by new mega-contract launches like Aetna and Highmark. However, the costs of these launches are crushing near-term profitability. Adjusted EBITDA fell 25% YoY to $28M, and the Medical Expense Ratio (MER) spiked to 95.3%. The 'J-curve' effect that management warned about in prior quarters is in full swing. While FY26 revenue guidance was raised to $2.6B-$2.7B, investors will be laser-focused on whether the promised margin recovery actually materializes in the second half of the year.
🐂 Bull Case
The company's Performance Suite revenue surged 81% YoY to $484.5M. High clinical complexity and rising costs are forcing health plans to outsource specialty care, validating Evolent's core value proposition.
Management confidently provided a preliminary 2027 outlook: >25% revenue growth and >$150M in Adjusted EBITDA, signaling that the current margin compression is strictly a temporary contract launch phase.
🐻 Bear Case
The Medical Expense Ratio hit 95.3%, squeezing gross margins. The company is relying on a steep, unproven margin ramp in H2 2026 to hit its full-year targets.
Outside the Performance Suite, both Specialty Technology and Administrative Services saw revenues decline. Combined with nearly $1B in net debt, execution missteps on new contracts could severely strain the balance sheet.
⚖️ Verdict: ⚪
Neutral. The top-line acceleration is undeniably impressive, but the 95.3% MER leaves zero room for error. The risk/reward remains balanced until Evolent proves it can bend the cost curve on its newest cohorts in Q3 and Q4.
Key Themes
Performance Suite Absorbs Massive New Launches
Accelerating. The Performance Suite remains the undisputed growth engine. Revenue skyrocketed from $267.9M in 25Q2 to $484.5M in 26Q2. This validates the strategy of taking on complex oncology and cardiology risk. A newly announced $300M oncology contract with an advanced imaging client (launching Dec 2026) proves the cross-selling pipeline remains highly active.
The 'J-Curve' Hits Hard: MER Spikes to 95.3%
Decelerating profitability. Management previously warned that the massive $900M cohort of new 2026 contracts (Aetna, Highmark) would require conservative initial reserving, dragging down margins early in the year. That reality has arrived: MER spiked to 95.3% (vs 84.9% ex-ECP a year ago). Adjusted EBITDA margin collapsed to 4.3% from 8.5%. The core concern is whether this is just conservative reserving or actual elevated medical trends.
Specialty Tech and Admin Services Stagnate
Reversing. While Performance Suite carries the top line, the legacy segments are lagging significantly. Specialty Technology revenue fell from $81.4M to $78.2M, and Administrative Services dropped from $55.9M to $48.0M YoY. Management previously attributed T&S weakness to expected exchange membership attrition, but the YoY declines highlight an increasing, singular reliance on the capital-intensive Performance Suite for growth.
Aggressive Cost Management Offsetting Gross Margin Compression
Stable. The company is actively cutting operating overhead to survive the MER spike. Adjusted SG&A actually dropped to $53.5M from $63.9M a year ago. Management credited its 'emerging AI-led operational model' for this discipline. By ruthlessly controlling corporate costs, Evolent managed to keep Adjusted EBITDA in positive territory ($28M) despite the massive surge in medical claims.
Macro Tailwind: Payers Desperate for Cost Containment
Accelerating. Broad industry pressures—specifically rising utilization and medical costs impacting health plans—are creating a durable countercyclical tailwind. Evolent noted these dynamics 'continue to drive robust demand' for its solutions, reinforcing why massive payers like Highmark and Aetna are willing to offload their complex specialty care risks.
Data Contradiction on Margin Path
In Q1, management guided to a full-year 2026 MER of ~93%. Q1 came in at 93.3%, and Q2 just hit 95.3%. To average ~93% for the full year, H2 MER must plummet into the high 80s / low 90s. While management is touting their 'disciplined' approach, the mathematical reality of hitting that full-year target demands a near-perfect execution ramp in Q3 and Q4.
Other KPIs
Cash flow remains pressured by the working capital demands of new contract launches. For the first six months of 2026, net cash used in operating activities was $10.3M, an improvement from a $25.8M use in the prior year period, but still negative. Management anticipates 'improved cash flow conversion' in 2027.
The balance sheet remains heavily leveraged. With only $115.7M in cash and cash equivalents against $966.5M in net long-term debt, financial flexibility is constrained. The CFO explicitly stated they are evaluating 'targeted debt reduction initiatives' to address the capital structure heading into 2027.
Guidance
Accelerating. Management raised the full-year guidance from the prior $2.4B-$2.6B range. At the midpoint ($2.65B), this represents a massive ~50% YoY growth vs the 2025 baseline, driven almost entirely by new Performance Suite implementations.
Stable. The range was tightened from the prior $110M-$140M, holding the midpoint relatively steady at $127.5M. Because H1 Adjusted EBITDA is only $50.1M, hitting the midpoint requires earning roughly $77.4M in H2—a dramatic step-up that demands immediate MER improvement.
Accelerating. Based on contracts currently in place and upcoming launches (including the new $300M imaging client), Evolent is already projecting another year of hyper-growth, pushing 2027 revenue well past the $3.2B mark.
Accelerating. The midpoint outlook signals that the 'J-curve' compression will pass, driven by improved Performance Suite care margins as the 2026 contract cohort matures.
Key Questions
MER Trajectory to Hit FY Targets
With Q2 MER hitting 95.3%, mathematical realities dictate a very steep drop in H2 to achieve the ~93% full-year expectation. Are you currently seeing the necessary reserve releases from the Aetna and Highmark cohorts in July/August to support this?
Debt Reduction Initiatives
The CFO mentioned evaluating 'targeted debt reduction initiatives.' Given the current cash levels and H1 cash burn, are you considering equity-linked avenues, or relying purely on the projected 2027 cash flow generation to deleverage?
Specialty Tech and Admin Services Declines
Both non-risk segments saw YoY revenue declines. How much of this is isolated to the expected exchange membership attrition versus structural churn or clients migrating directly to the Performance Suite?